{
    "clinical_study": {
        "@rank": "144595", 
        "arm_group": {
            "arm_group_label": "Patients with risk of VTE", 
            "description": "Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release"
        }, 
        "brief_summary": {
            "textblock": "The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the\n      clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the\n      safety and effectiveness information about Eliquis in general practice"
        }, 
        "brief_title": "Eliquis Regulatory Post Marketing Surveillance (rPMS)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed data release\n\n          -  Patients undergoing elective total hip replacement arthroplasty or elective total\n             knee replacement arthroplasty\n\n        Exclusion Criteria:\n\n          -  Being treated for an indication not approved for the use of Eliquis\u00ae in Korea\n\n          -  Is contraindicated for the use of Eliquis\u00ae as described in the Korean label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic Patients must be \u226519 years of age, at risk for venous thrombosis, and\n        have elected to undergo total hip replacement arthroplasty or total knee replacement\n        arthroplasty will be included in this study"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885585", 
            "org_study_id": "CV185-222"
        }, 
        "intervention": {
            "arm_group_label": "Patients with risk of VTE", 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "Eliquis"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 1, 2013", 
        "number_of_groups": "1", 
        "official_title": "Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events (AEs) and serious AEs", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after last study drug dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}